Paper41514652
Spontaneous cSCC Murine Model Shows Limited Response to PD-1 Blockade and Radiation Combination Therapy.
Hosseini TM and 8 others. Cancers (Basel), 2025. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. Spontaneous cSCC Murine Model Shows Limited Response to PD-1 Blockade and Radiation Combination Therapy. Papers, record 41514652. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41514652
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Spontaneous cSCC Murine Model Shows Limited Response to PD-1 Blockade and Radiation Combination Therapy.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
Grants3
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| 1KL2TR001444-08 | NIH HHS | United States | KL2TR001444 | PubMed and NIH | NIH RePORTER |
| IRG-19-230-48-IRG | American Cancer Society | PubMed | PubMed | ||
| 1K08CA276999-01A1 | NIH HHS | United States | K08CA276999 | PubMed and NIH | NIH RePORTER |
References34
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 28819064 | The Tumor Microenvironment Regulates Sensitivity of Murine Lung Tumors to PD-1/PD-L1 Antibody Blockade. | Cancer Immunol Res | 2017 | https://conductscience.org/library/papers/28819064 | PubMed |
| 2 | 41339105 | Immunomodulation of UVB-induced regulatory T cells prevents the establishment of squamous cell carcinoma. | J Immunother Cancer | 2025 | https://conductscience.org/library/papers/41339105 | PubMed |
| 3 | 38511232 | Immune checkpoint inhibitor monotherapy is sufficient to promote microenvironmental normalization via the type I interferon pathway in PD-L1-expressing head and neck cancer. | Mol Oncol | 2024 | https://conductscience.org/library/papers/38511232 | PubMed |
| 4 | 34448958 | Immunotherapy for Non-melanoma Skin Cancer. | Curr Oncol Rep | 2021 | https://conductscience.org/library/papers/34448958 | PubMed |
| 5 | 41319712 | Extended follow-up outcomes of patients with advanced cutaneous squamous cell carcinoma treated with cemiplimab on EMPOWER-CSCC-1: A retrospective cohort study. | J Am Acad Dermatol | 2026 | https://conductscience.org/library/papers/41319712 | PubMed |
| 6 | 30736857 | Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts. | J Immunother Cancer | 2019 | https://conductscience.org/library/papers/30736857 | PubMed |
| 7 | 22916792 | Sequencing and characterization of the FVB/NJ mouse genome. | Genome Biol | 2012 | https://conductscience.org/library/papers/22916792 | PubMed |
| 8 | 19713956 | Multi-stage chemical carcinogenesis in mouse skin: fundamentals and applications. | Nat Protoc | 2009 | https://conductscience.org/library/papers/19713956 | PubMed |
| 9 | 30497667 | Cutaneous Squamous Cell Carcinoma. | Hematol Oncol Clin North Am | 2019 | https://conductscience.org/library/papers/30497667 | PubMed |
| 10 | 33653716 | Targeted Therapy Given after Anti-PD-1 Leads to Prolonged Responses in Mouse Melanoma Models through Sustained Antitumor Immunity. | Cancer Immunol Res | 2021 | https://conductscience.org/library/papers/33653716 | PubMed |
| 11 | 32331425 | Cutaneous Squamous Cell Carcinoma: From Biology to Therapy. | Int J Mol Sci | 2020 | https://conductscience.org/library/papers/32331425 | PubMed |
| 12 | 32793604 | Resistance Mechanisms of Anti-PD1/PDL1 Therapy in Solid Tumors. | Front Cell Dev Biol | 2020 | https://conductscience.org/library/papers/32793604 | PubMed |
| 13 | 34680282 | Overcoming Resistance to Immunotherapy in Advanced Cutaneous Squamous Cell Carcinoma. | Cancers (Basel) | 2021 | https://conductscience.org/library/papers/34680282 | PubMed |
| 14 | 39245360 | A phase 2 open-label study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (EMPOWER-CSCC-1): Final long-term analysis of groups 1, 2, and 3, and primary analysis of fixed-dose treatment group 6. | J Am Acad Dermatol | 2025 | https://conductscience.org/library/papers/39245360 | PubMed |
| 15 | 34208111 | Anti-PD1/PD-L1 Immunotherapy for Non-Small Cell Lung Cancer with Actionable Oncogenic Driver Mutations. | Int J Mol Sci | 2021 | https://conductscience.org/library/papers/34208111 | PubMed |
| 16 | 30158594 | Time-Series Analysis of Tumorigenesis in a Murine Skin Carcinogenesis Model. | Sci Rep | 2018 | https://conductscience.org/library/papers/30158594 | PubMed |
| 17 | 27358187 | Cutaneous Squamous Cell Carcinoma: A Review of High-Risk and Metastatic Disease. | Am J Clin Dermatol | 2016 | https://conductscience.org/library/papers/27358187 | PubMed |
| 18 | 29332704 | Cutaneous squamous cell carcinoma: Incidence, risk factors, diagnosis, and staging. | J Am Acad Dermatol | 2018 | https://conductscience.org/library/papers/29332704 | PubMed |
| 19 | 32673170 | Pembrolizumab Monotherapy for Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma: A Single-Arm Phase II Trial (KEYNOTE-629). | J Clin Oncol | 2020 | https://conductscience.org/library/papers/32673170 | PubMed |
| 20 | 34592000 | Epidemiology of advanced cutaneous squamous cell carcinoma. | J Eur Acad Dermatol Venereol | 2022 | https://conductscience.org/library/papers/34592000 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Cited by
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41514652
GET https://conductscience.org/api/papers/v1/41514652/references?page=2